Viekira Pak

Product manufactured by Abbvie Inc.

Application Nr Approved Date Route Status External Links
NDA206619 None None None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Viekira Pak Is Indicated For The Treatment Of Adult Patients With Chronic Hepatitis C Virus (hcv) [see Dosage And Administration ( 2.2 ) And Clinical Studies ( 14 )] : Genotype 1b Without Cirrhosis Or With Compensated Cirrhosis Genotype 1a Without Cirrhosis Or With Compensated Cirrhosis For Use In Combination With Ribavirin. Viekira Pak Is Indicated For The Treatment Of Adult Patients With Chronic Hepatitis C Virus (hcv): Genotype 1b Without Cirrhosis Or With Compensated Cirrhosis Genotype 1a Without Cirrhosis Or With Compensated Cirrhosis For Use In Combination With Ribavirin. Viekira Pak Includes Ombitasvir, A Hepatitis C Virus Ns5a Inhibitor, Paritaprevir, A Hepatitis C Virus Ns3/4a Protease Inhibitor, Ritonavir, A Cyp3a Inhibitor And Dasabuvir, A Hepatitis C Virus Non-Nucleoside Ns5b Palm Polymerase Inhibitor. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Comments